Cassiopeia
Janesville, Wisconsin
OVERVIEW
A purpose-built n.c.a. Lu-177 production facility
Some cancers stop responding to treatment. Lutetium-177, a therapeutic radioisotope, gives
doctors another option. Paired with a molecule that seeks out cancer cells, it delivers radiation directly to the tumor while limiting damage to healthy tissue. There are two approved Lu-177 therapies now in use and more than 200 active clinical trials underway.
Cassiopeia is where we make Ilumira, our non-carrier-added Lu-177, under the cGMP standards the FDA and EMA require. The facility is designed to support roughly 100,000 doses a year.
We control every step, from securing enriched ytterbium-176, through final shipment, and our process recovers more than 95% of ytterbium during production.
Key Facility Stats
Primary Product
Ilumira – Lutetium177 chloride
Status
Production at commercial volume
Distinction
Global source of llumira
System Type
Radiochemical & pharmaceutical manufacturing
Energy Output
~100,000 doses/year
Chemists once called lutetium “cassiopeium.” We chose the name Cassiopeia for the building where we make our n.c.a. Lu-177, delivered weekly worldwide.
VIDEO TOUR
Tour Cassiopeia
Step inside Cassiopeia. See where llumira is made, from start to finish.
PHOTO GALLERY
See inside Cassiopeia
Inside Cassiopeia: the rooms, equipment and people behind every vial of
llumira.
WHAT HAPPENS HERE
Capabilities & specs
n.c.a. Lu-177 production
Cassiopeia produces llumira, that’s used in cancer treatments worldwide.
Radiochemical processing
We separate the n.c.a. Lu-177 and purify it to 99.9% radionuclidic purity, then fill and
package it for shipment worldwide.
cGMP manufacturing
Every batch is made to current Good Manufacturing Practice standards.
Quality & regulatory systems
Cassiopeia operates under an accepted FDA Drug Master File and holds European Marketing Authorization for llumira.
Scalable capacity
Capacity today is roughly 100,000 doses a year.
Global distribution
llumira ships from Cassiopeia to CDMOs, researchers, and providers on six continents.
NEWS FEED
Cassiopeia in the news
FACILITIES
One platform, multiple facilities
Across our facilities, the same core capabilities support fusion-system development, neutron testing, medical-isotope production, radiochemistry and commercial operations.
Janesville, Wisconsin
Once complete, we expect Chrysalis to be among the largest medical isotope production facilities of molybdenum-99 (Mo-99) in the world. Producing it in the U.S. with fusion-driven technology, our facility will close a supply gap left by end-of-life reactors overseas and ease real shortages for hospitals.
Janesville, Wisconsin
Cassiopeia produces Ilumira, our non-carrier-added lutetium-177 for cancer treatment. Ilumira’s consistently high quality supports precise, reliable dosing for treatment programs worldwide.
Fitchburg, Wisconsin
Heliopolis is our 47,500 square-foot manufacturing site in Fitchburg, Wis. This is where we design, build and test entire first-of-a-kind fusion systems. Electromagnets, ion sources, tritium handling equipment — if it doesn’t exist yet, we build it here.
Janesville, Wisconsin
Building One runs our radiation effects testing system at approximately 46 trillion fusion reactions per second. Aerospace and defense customers test how their electronics hold up under radiation here, while our radiochemists develop the separation science behind our isotopes and fuel recycling.
Fitchburg, Wisconsin
Our imaging center uses neutron radiography and CT to see inside components and catch flaws invisible to X-rays. We’re one of a limited number of commercial facilities worldwide that can do this without relying on a nuclear reactor.
North Billerica, Massachusetts
Our Isotope Delivery Campus produces and distributes SPECT imaging agents that support millions of diagnostic procedures annually for cardiac, pulmonary, thyroid and other applications for hospitals and imaging centers across North America.